Exercise of options
Faron Pharmaceuticals Ltd. (“Faron”) Exercise of options Issue of equity Company announcement, October 27, 2023 at 7:15 a.m. BST / 9:15 a.m. EEST TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical- stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that it has received notifications from option holders to exercise 2015B options over 22,306 in the Company at an exercise price of EUR 2.90 (approx. GBP 2.48) per share and 2015D options over 25,873 shares in the